Recombinant anti-CD25 immunotoxin RFT5(S
✍
Stefan Barth; Michael Huhn; Bärbel Matthey; Roland Schnell; Samir Tawadros; Timo
📂
Article
📅
2000
🏛
John Wiley and Sons
🌐
French
⚖ 284 KB
Since clinical phase-I/II trials in patients with resistant Hodgkin's lymphoma treated with the chemically linked anti-CD25 ricin-A-chain immunotoxin RFT5-SMPT-dgA indicate promising results for patients with minimal residual disease, we constructed a new immunotoxin by fusing the RFT5 single-chain